Phosphoinositide 3-kinase (PI3K) Inhibitors
Customize your policy alerts
Sign up for Premera Bluecross Policy 5.01.592 alerts
Get alerted when Policy 5.01.592 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical-necessity review and prior authorization for specified oral PI3K pathway inhibitors used for oncology, immunologic, and PIK3CA-related overgrowth conditions. Coverage depends on drug-specific diagnosis, age, mutation or biomarker findings, prior therapy, combination therapy, prescriber specialty, dosing, and response criteria.
The 2021 update added coverage criteria for umbralisib for marginal zone lymphoma and follicular lymphoma.
The 2022 update removed duvelisib coverage for relapsed or refractory follicular lymphoma after the manufacturer voluntarily withdrew the indication.
The 2022 update removed copanlisib coverage for chronic lymphocytic leukemia and small lymphocytic lymphoma because the drug was not FDA approved or recommended by NCCN for those conditions.
The 2022 update added coverage for alpelisib products Vijoice and Piqray for PIK3CA-related overgrowth spectrum.
The 2023 update added coverage criteria for leniolisib for activated phosphoinositide 3-kinase delta syndrome in adults and pediatric individuals age 12 years and older.
The 2024 update added coverage criteria for capivasertib for certain individuals with breast cancer.
The 2024 update removed idelalisib coverage criteria for certain follicular lymphoma and small lymphocytic lymphoma uses because those indications were removed from prescribing information.
The 2024 update revised alpelisib coverage criteria to include certain premenopausal and perimenopausal women with breast cancer.
Added coverage criteria for Truqap (capivasertib) in adults with metastatic androgen pathway modulation-naive or sensitive prostate cancer that is PTEN-deficient.
Removed coverage criteria for Aliqopa (copanlisib) because the medication has been discontinued.
Removed HCPCS code J9057 from the policy.
Changed the initial authorization period for all other reviews of oral drugs listed in the policy from 3 months to 6 months.
Limited the Piqray (alpelisib) breast-cancer dose to 300 mg once daily.
Removed the ECOG performance status 0 or 1 requirement from Itovebi (inavolisib) criteria.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.